The effect of a single SMARCA4 exon deletion on RNA splicing: Implications for variant classification

BACKGROUND Exon deletions are generally considered pathogenic, particularly when they are located out of frame. Here, we describe a pediatric, female patient presenting with hypercalcemia and a small cell carcinoma of the ovary, hypercalcemic type, and carrying a germline de novo SMARCA4 exon 14 deletion. METHODS The SMARCA4 deletion was identified by whole genome sequencing, and the effect on the RNA level was examined by gel- and capillary electrophoresis and nanopore sequencing. RESULTS The deletion was in silico predicted to be truncating, but RNA analysis revealed two major transcripts with deletion of exon 14 alone or exon 14 through 15, where the latter was located in-frame. Because the patient's phenotype matched that of other patients with pathogenic germline variants in SMARCA4, the deletion was classified as likely pathogenic. CONCLUSION We propose to include RNA analysis in classification of single-exon deletions, especially if located outside of known functional domains, as this can identify any disparate effects on the RNA and DNA level, which may have implications for variant classification using the American College of Medical Genetics and Genomics guidelines.

[1]  H. Okkels,et al.  Genetic predisposition & evolutionary traces of pediatric cancer risk: A prospective 5-year population-based genome sequencing study of children with CNS tumors. , 2022, Neuro-oncology.

[2]  N. Tommerup,et al.  Nationwide germline whole genome sequencing of 198 consecutive pediatric cancer patients reveals a high incidence of cancer prone syndromes , 2020, PLoS genetics.

[3]  M. Bycroft,et al.  Structure of the BRK domain of the SWI/SNF chromatin remodeling complex subunit BRG1 reveals a potential role in protein–protein interactions , 2020, Protein science : a publication of the Protein Society.

[4]  D. Lin,et al.  Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts. , 2019, Gynecologic oncology.

[5]  S. Bonache,et al.  Incorporation of semi‐quantitative analysis of splicing alterations for the clinical interpretation of variants in BRCA1 and BRCA2 genes , 2019, Human mutation.

[6]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[7]  Diego Garrido-Martín,et al.  ggsashimi: Sashimi plot revised for browser- and annotation-independent splicing visualization , 2018, PLoS Comput. Biol..

[8]  Abramowicz Anna,et al.  Splicing mutations in human genetic disorders: examples, detection, and confirmation , 2018, Journal of Applied Genetics.

[9]  Heng Li,et al.  Minimap2: pairwise alignment for nucleotide sequences , 2017, Bioinform..

[10]  S. Giglio,et al.  SMARCA4 inactivating mutations cause concomitant Coffin–Siris syndrome, microphthalmia and small‐cell carcinoma of the ovary hypercalcaemic type , 2017, The Journal of pathology.

[11]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[12]  F. Couch,et al.  Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing. , 2014, Clinical chemistry.

[13]  W. Foulkes,et al.  Familial rhabdoid tumour 'avant la lettre'—from pathology review to exome sequencing and back again , 2013, The Journal of pathology.

[14]  R. Siebert,et al.  Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. , 2010, American journal of human genetics.